The Purpose of this Study: Whether an investigational drug called RGN-259 Thymosin Beta 4 eye drops solution is a safe and effective option for the treatment of neurotrophic keratopathy.

ClinicalTrials.gov ID: NCT05555589. Sponsor: ReGenTree, LLC. A Phase 3, Multi-Center, Randomized, Parallel, Double Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of Neurotrophic Keratopathy (SEER-2) 

Currently Enrolling 

To enroll in this study at please contact Susan Sherouse via ssherous@usf.edu or (813) 974-0948. 

The Purpose of this Study: to evaluate the efficacy, safety and tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of efgartigimod PH20 SC in participants with active, moderate-to-severe thyroid eye disease, compared with placebo PH20 SC.

ClinicalTrials.gov ID: NCT06307613. Sponsor: argenx US Inc. Phase 3 Study to Evaluate the Safety and Efficacy of Self-administered efgartigimod SC injection for Adults with Thyroid Eye Disease (TED).

Currently Enrolling 

To enroll in this study at please contact Susan Sherouse via ssherous@usf.edu or (813) 974-0948. 

The Purpose of this Study: to evaluate whether simultaneous treatment with spectacles and patching has an equivalent VA outcome compared with sequential treatment, first with spectacles alone followed by patching (if needed), for previously untreated amblyopia children 3 to 13 years of age.

ClinicalTrials.gov ID: NCT04378790. Sponsor: Jaeb Center for Health Research. A Randomized Trial to Evaluate Sequential vs Simultaneous Patching (ATS22).

Currently Enrolling 

To enroll in this study at please contact Susan Sherouse via ssherous@usf.edu or (813) 974-0948. 

The Purpose of this Study: to determine if treatment with 1 hour per day 6 days per week of watching dichoptic movies/shows wearing the Luminopia headset is non-inferior to treatment with 2 hours of patching per day 7 days per week with respect to change in amblyopic eye distance VA from randomization to 26 weeks.

ClinicalTrials.gov ID: NCT06380517. Sponsor: Jaeb Center for Health Research.: Dichoptic Treatment for Amblyopia in Children 4 to 7 Years of Age (ATS23).

Currently Enrolling 

To enroll in this study at please contact Susan Sherouse via ssherous@usf.edu or (813) 974-0948. 

The Purpose of this Study: is to compare the effectiveness of Luminopia and Vivid Vision while wearing optical correction.

ClinicalTrials.gov ID: NCT06524882. Sponsor: Jaeb Center for Health Research. A randomized trial of dichoptic Rx for manblipoia in children 8-12 (ATS24).

Currently Enrolling

To enroll in this study at please contact Susan Sherouse via ssherous@usf.edu or (813) 974-0948. 

ClinicalTrials.gov ID: NCT05555589. Sponsor: AbbVie. Long-term Safety and Efficacy Extension Trial of Bimatoprost SR (Maia)

Ongoing Trials/Closed for Recruitment

For inquiries please contact Susan Sherouse via ssherous@usf.edu or (813) 974-0948.